anonymous
Guest
anonymous
Guest
This is not standard SEC or FDA language. CG was given a 5 year approval in 2015. This means starting year 3, 2018 they have to start submitting data on the efficacy of the test. I have spoken to over 100 GI's that said 75% of the CG tests are wrong! They get a lot of positives, go in for the colonoscopy and find nothing. They are not happy with the test and therefore more and more are not ordering it. CG is not here to stay. There are multiple tests on the way that will wipe out this test. There are several blood tests seeking FDA approval and 2 urine based tests seeking FDA approval. If these test get approval, CG will be gone. Give the patient a choice and they will choose urine, blood then stool in that order. CG was meant to be a 3-5 year test at best. Build up the volume and stock price and then dump the company. This is not a long term test. When the data is submitted later this year to the FDA, the approval may be pulled. The data will not back up the specificity and sensitivity. The test is just not all it promised to be!
You're wrong! Every GI I talk with uses CG and embraces the need for what we are doing. Are there other companies trying to bring a better test forward? Sure. Are we? Sure. That's not a threat. There is more to ES than CG. You wish us to fail but we are expanding and growing and here to stay. Sorry you are so determined to keep coming back to this page, but nobody believes you except the haters like you who want us to fail.
and your liquid biopsy test that's the closest? Their study was 600 patients in Taiwan. More than half had CRC... that is not close to an accurate study. Call me when they do a study of 10k+ of a typical population. If they started today on the 10K study, they are 3-4 years out from bringing the test to market.
No-one has been able to get a liquid biopsy with more sensitivity than in the mid 40's. It will happen one day and ES might be the company that does it. The race is on!